Karyopharm rises after IPO prices at $108.8M


Save Story
Leer en espaƱol

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

NEW YORK (AP) - Shares of Karyopharm Therapeutics rose Wednesday after the biotechnology company's initial public offering raised $108.8 million.

Karyopharm sold 6.8 million shares in an IPO priced at $16 per share, the high end of its expectations.

The stock gained 15 cents to $16.15 in afternoon trading after trading as high as $19.09 earlier in the day.

Karyopharm Therapeutics Inc. had previously expected to sell 5.7 million shares.

The underwriters of the IPO will have the option to buy 1 million more shares at the same price.

The Natick, Mass., company is running clinical trials of treatments for cancer and is also researching treatments for autoimmune, inflammatory and viral illnesses and a medication designed to speed up wound healing.

Its shares are trading on the Nasdaq Global Select Market under the ticker symbol "KPTI."

(Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)

Most recent Business stories

Related topics

Business

STAY IN THE KNOW

Get informative articles and interesting stories delivered to your inbox weekly. Subscribe to the KSL.com Trending 5.
By subscribing, you acknowledge and agree to KSL.com's Terms of Use and Privacy Policy.

KSL Weather Forecast